Altrient introduces three new supplements
LAS VEGAS — Altrient is launching three new nutritional supplements that will be available on the company’s website.
The company said the lineup includes:
Altrient C, a full-potency vitamin C formula (which touts 1,000 mg of vitamin C in each packet);
Altrient ME, which combines B vitamins, essential trace minerals and cinnamon extract to boost energy and reduce the harmful byproducts of cell metabolism (and contains 313.5 mg of the "metabolic enhancement" formula in each packet); and
Altrient GSH, which delivers 450 mg of glutathione sulfhydryl, an antioxidant, in each packet.
All of the supplements use a proprietary liposome encapsulated delivery system that’s designed to transport pure, essential nutrients throughout the body, the company said.
Altrient products will be delivered in cartons of 30 single-serving packets.
Blowfish seeks to cure hangovers
NEW YORK — A new over-the-counter drug designed to treat hangovers has entered the market.
Blowfish is an effervescent that touts 500 mg aspirin and 60 mg caffeine and can be used for the following indications:
For the temporary relief of minor aches and pains associated with a hangover;
Helps restore mental alertness or wakefulness when experiencing fatigue or drowsiness associated with a hangover; and
For the temporary relief of headaches or body aches and pains alone.
Users are instructed to dissolve two tablets in a 16-oz. glass of water.
Blowfish is available in 12-tablet and 50-tablet boxes at Ricky’s NYC stores and soon will be available in Duane Reade stores.
FDA to decide on relaxing merchandising restrictions for Plan B
WASHINGTON — The Food and Drug Administration will decide on Wednesday whether to remove merchandising restrictions on the emergency contraceptive Plan B and allow the product to be merchandised in the front-end without age restrictions, according to a report published Monday in the Washington Post.
According to the report, Teva Pharmaceutical Industries requested that the FDA relax merchandising restrictions based on two new consumer usage studies showing that pre-teen and teenage women appropriately self-selected use of the emergency contraceptive. One study involving 335 girls ages 12 to 17 years showed that between 72% and 96% of them understood the proposed package label well enough to use the drug safely and effectively on their own. The second study, involving about 300 girls ages 11 to 16 years, showed that they could use the product properly and safely, according to Teva.
Separately, a hearing is scheduled for Dec. 13 on a motion to declare the agency in contempt of court for failing to review its decision to leave age restrictions in place as part of a suit filed against the agency by the Center for Reproductive Rights.
For the full story, click here.